Explore how generative AI is reshaping small molecule drug discovery—from latent chemical spaces and graph neural networks to AI-designed compounds now advancing in oncology, CNS, and rare disease pipelines.
Discover how generative AI is transforming small molecule drug discovery by designing novel compounds in silico, optimizing potency and ADMET profiles, and enabling closed-loop discovery cycles across oncology, fibrosis, infectious disease, and CNS disorders.
Learn how generative AI models—VAEs, GANs, reinforcement learning, and diffusion models—are revolutionizing small molecule drug discovery by designing novel, target‑optimized compounds faster and more efficiently than traditional methods.